TY - JOUR
T1 - Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings
T2 - HEARTS 2.0 Phase 1
AU - Rosende, Andres
AU - Romero, Cesar
AU - Dipette, Donald J.
AU - Brettler, Jeffrey
AU - van der Stuyft, Patrick
AU - Satheesh, Gautam
AU - Perel, Pablo
AU - Chapman, Niamh
AU - Moran, Andrew E.
AU - Schutte, Aletta E.
AU - Sharman, James E.
AU - Irazola, Vilma
AU - Huffman, Mark D.
AU - Campbell, Norm R.C.
AU - Salam, Abdul
AU - Lanas, Fernando
AU - Coca, Antonio
AU - Garcia-Zamora, Sebastian
AU - Ferreiro, Alejandro
AU - Lopez-Jaramillo, Patricio
AU - Rico-Fontalvo, Jorge
AU - Ridley, Emily
AU - Picone, Dean
AU - Flood, David
AU - Piñeiro, Daniel José
AU - Ojeda, Carolina Neira
AU - Rodriguez, Gonzalo
AU - Wellmann, Irmgardt A.
AU - Orias, Marcelo
AU - Rivera, Marcela
AU - Reyes, Matías Villatoro
AU - Onuma, Oyere
AU - Ramroop, Shaun
AU - Khan, Taskeen
AU - Gonzalez, Yamile Valdes
AU - Barroso, Weimar Kunz Sebba
AU - Plavnik, Frida L.
AU - Zuniga, Eric
AU - Grassani, Ana María
AU - Tajer, Carlos
AU - Zaidel, Ezequiel
AU - Marin, Marcos J.
AU - Cyr-Philbert, Shana
AU - Amorin, Ignacio
AU - Aguilera, Miguel Angel Diaz
AU - Bortolotto, Luiz
AU - Avezum, Alvaro
AU - Ribeiro, Antonio Luiz P.
AU - Tobe, Sheldon
AU - Aumala, Teresa
AU - Angell, Sonia
AU - Lavados, Pablo
AU - Martins, Sheila Ouriques
AU - Echeverri, Ana Munera
AU - Jaffe, Marc G.
AU - Prabhakaran, Dorairaj
AU - Parati, Gianfranco
AU - Zhang, Xin Hua
AU - Rodgers, Anthony
AU - Yusuf, Salim
AU - Whelton, Paul K.
AU - Ordunez, Pedro
N1 - Publisher Copyright:
© 2025 Pan American Health Organization.
PY - 2025
Y1 - 2025
N2 - Background: HEARTS in the Americas is the regional adaptation of the WHO Global HEARTS Initiative, aimed at helping countries enhance hypertension and cardiovascular disease (CVD) risk management in primary care settings. Its core implementation tool, the HEARTS Clinical Pathway, has been adopted by 28 countries. To improve the care of hypertension, diabetes, and chronic kidney disease (CKD), HEARTS 2.0 was developed as a three-phase process to integrate evidence-based interventions into a unified care pathway, ensuring consistency across fragmented guidelines. This paper focuses on Phase 1, highlighting targeted interventions to improve and update the HEARTS Clinical Pathway. Methods: First, the coordinating group defined the project’s scope, objectives, principles, methodological framework, and tools. Second, international experts from different disciplines proposed interventions to enhance the HEARTS Clinical Pathway. Third, the coordinating group harmonized these proposals into unique interventions. Fourth, experts appraised the appropriateness of the proposed interventions on a 1-to-9 scale using the adapted RAND/UCLA Appropriateness Method. Finally, interventions with a median score above 6 were deemed appropriate and selected as candidates to enhance the HEARTS Clinical Pathway. Results: Building on the existing HEARTS Clinical Pathway, 45 unique interventions were selected, including community-based screening, early detection and management of risk factors, lower blood pressure thresholds for diagnosing hypertension in high-CVD-risk patients, reinforcement of single-pill combination therapy, inclusion of sodium-glucose cotransporter-2 inhibitors for patients with diabetes, CKD, or heart failure, expanded roles for non-physician health workers in team-based care, and strengthened clinical documentation, monitoring, and evaluation. Conclusion: HEARTS 2.0 Phase 1 identifies key interventions to integrate and improve hypertension and cardiovascular-kidney-metabolic care within primary care, enabling their seamless incorporation into a unified and effective clinical pathway. This process will inform an update to the HEARTS Clinical Pathway, optimizing resources, reducing care fragmentation, improving care delivery, and advancing health equity, thereby supporting global efforts to combat the leading causes of death and disability.
AB - Background: HEARTS in the Americas is the regional adaptation of the WHO Global HEARTS Initiative, aimed at helping countries enhance hypertension and cardiovascular disease (CVD) risk management in primary care settings. Its core implementation tool, the HEARTS Clinical Pathway, has been adopted by 28 countries. To improve the care of hypertension, diabetes, and chronic kidney disease (CKD), HEARTS 2.0 was developed as a three-phase process to integrate evidence-based interventions into a unified care pathway, ensuring consistency across fragmented guidelines. This paper focuses on Phase 1, highlighting targeted interventions to improve and update the HEARTS Clinical Pathway. Methods: First, the coordinating group defined the project’s scope, objectives, principles, methodological framework, and tools. Second, international experts from different disciplines proposed interventions to enhance the HEARTS Clinical Pathway. Third, the coordinating group harmonized these proposals into unique interventions. Fourth, experts appraised the appropriateness of the proposed interventions on a 1-to-9 scale using the adapted RAND/UCLA Appropriateness Method. Finally, interventions with a median score above 6 were deemed appropriate and selected as candidates to enhance the HEARTS Clinical Pathway. Results: Building on the existing HEARTS Clinical Pathway, 45 unique interventions were selected, including community-based screening, early detection and management of risk factors, lower blood pressure thresholds for diagnosing hypertension in high-CVD-risk patients, reinforcement of single-pill combination therapy, inclusion of sodium-glucose cotransporter-2 inhibitors for patients with diabetes, CKD, or heart failure, expanded roles for non-physician health workers in team-based care, and strengthened clinical documentation, monitoring, and evaluation. Conclusion: HEARTS 2.0 Phase 1 identifies key interventions to integrate and improve hypertension and cardiovascular-kidney-metabolic care within primary care, enabling their seamless incorporation into a unified and effective clinical pathway. This process will inform an update to the HEARTS Clinical Pathway, optimizing resources, reducing care fragmentation, improving care delivery, and advancing health equity, thereby supporting global efforts to combat the leading causes of death and disability.
KW - Cardiovascular Diseases
KW - Chronic
KW - Primary Health Care
KW - Renal Insufficiency
KW - Stroke
KW - diabetes mellitus
KW - hypertension
UR - https://www.scopus.com/pages/publications/105007931068
U2 - 10.5334/gh.1428
DO - 10.5334/gh.1428
M3 - Article
C2 - 40454106
AN - SCOPUS:105007931068
SN - 2211-8160
VL - 20
JO - Global Heart
JF - Global Heart
IS - 1
M1 - 45
ER -